Nuwellis Inc
$ 1.61
-4.73%
24 Feb - close price
- Market Cap 2,202,500 USD
- Current Price $ 1.61
- High / Low $ 1.78 / 1.60
- Stock P/E N/A
- Book Value 2.86
- EPS -250.62
- Next Earning Report 2026-03-10
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.93 %
- ROE -4.67 %
- 52 Week High 56.28
- 52 Week Low 1.60
About
Nuwellis, Inc., a medical device company, focuses on the development, manufacture and marketing of medical devices used in ultrafiltration therapy. The company is headquartered in Eden Prairie, Minnesota.
Analyst Target Price
$11.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-12 | 2025-08-14 | 2025-05-05 | 2025-03-03 | 2024-11-11 | 2024-08-13 | 2024-05-07 | 2024-03-05 | 2023-11-07 | 2023-08-08 | 2023-05-09 | 2023-02-28 |
| Reported EPS | 0.56 | -60.98 | -0.69 | -0.44 | 1.74 | -18.85 | -0.6 | -1.56 | -1.81 | -3.65 | -5.76 | -5 |
| Estimated EPS | -0.23 | -0.34 | -0.45 | -0.43 | -1.28 | -8.24 | -1.06 | -1.39 | -3.11 | -4.02 | -3.79 | -17.09 |
| Surprise | 0.79 | -60.64 | -0.24 | -0.01 | 3.02 | -10.61 | 0.46 | -0.17 | 1.3 | 0.37 | -1.97 | 12.09 |
| Surprise Percentage | 343.4783% | -17835.2941% | -53.3333% | -2.3256% | 235.9375% | -128.7621% | 43.3962% | -12.2302% | 41.8006% | 9.204% | -51.9789% | 70.7431% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-10 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: NUWE
2026-02-24 12:52:29
Nuwellis, Inc. announced it will release its fourth quarter and full year 2025 financial results on March 10, 2026. The company will host a conference call and webcast to discuss these results and provide a business update. Nuwellis specializes in medical technology for cardiorenal conditions, including the Aquadex SmartFlow system.
2026-02-05 04:58:01
Nuwellis (NUWE) has completed a $5 million financing through a private placement and warrant exercise, intending to use the funds for working capital and corporate purposes. Concurrently, Nuwellis is acquiring Rendiatech Ltd., an Israeli company specializing in kidney monitoring products, and has appointed Carisa Schultz as its new CFO. Despite these strategic moves, which aim to strengthen the company’s technology and market position, TipRanks' AI Analyst assigned NUWE a Neutral rating due to weak financial performance and ongoing equity dilution concerns.
2026-02-03 05:29:15
Nuwellis, Inc. (Nasdaq: NUWE) has entered into a definitive agreement to acquire Rendiatech Ltd., an Israeli medical technology company specializing in automated kidney function monitoring. This acquisition will expand Nuwellis's portfolio beyond therapeutic fluid management into real-time renal diagnostics, aiming to improve early detection of kidney stress and clinical decision-making. The transaction is expected to close after customary conditions are met, allowing Nuwellis to leverage its existing commercial infrastructure for integration and future development of Rendiatech’s Clarity™ system.
2026-02-02 17:29:10
Nuwellis, Inc. has announced a private placement and warrant inducement transaction expected to generate approximately $5.0 million in gross proceeds. The company will sell 994,537 shares of common stock (or pre-funded warrants) and warrants to purchase 1,989,074 shares, priced at-the-market. Additionally, an existing investor agreed to immediately exercise certain outstanding warrants at a reduced exercise price, in exchange for new unregistered warrants.
2026-01-30 19:57:45
Nuwellis, Inc. has entered a definitive agreement to acquire Rendiatech Ltd., an Israeli medical technology company specializing in automated kidney function monitoring. This acquisition will expand Nuwellis's portfolio from therapeutic fluid management to real-time renal diagnostics, reinforcing its cardiorenal strategy. The integration of Rendiatech's Clarity™ system is expected to provide automated, continuous renal monitoring and support enhanced clinical decision-making.
2026-01-30 19:57:44
Nuwellis (Nasdaq: NUWE) has entered into a definitive agreement to acquire Rendiatech Ltd., an Israeli medical technology company specializing in automated kidney function monitoring. This acquisition will expand Nuwellis' cardiorenal portfolio to include real-time kidney diagnostics, specifically Rendiatech's Clarity™ automated continuous urine-output monitoring system. The deal, which enhances Nuwellis' offerings beyond fluid removal and aims for earlier detection of kidney stress, is subject to customary closing conditions.
